To: RoadyHD who wrote (12546 ) 12/15/2019 8:40:46 AM From: old 'n cranky Read Replies (2) | Respond to If that were the arrangement, the funding by NNVC of TheraCour wouldn't be problematic. 10% gross profit royalty (net sales less COGS and less amortised development costs that were paid to TheraCour) Do real companies really do that? Not the last bit, of course, but the calculation of a royalty based on Gross Profits (net sales less COGS). Net sales can occasionally have gray areas, but the idea of having to provide documentation for a COGS calculation that is indisputable sounds like it provides great opportunity for disagreement.In response to questions from shareholders regarding a timeline for the Company's first IND filing with the US FDA, Dr. Diwan reported that the timeline was extremely dependent on external collaborators , and as such, the Company could not provide a projected date for filing of the IND. However, the Company anticipates that the IND package could be ready in the next eight weeks or so, if all goes well, and if we obtain all of the external reports expeditiously. He added that the IND package is then required to be converted into the "eCTD" ("electronic Common Technical Document") format in order to be submitted to the US FDA. He stressed that this timeline projection had a high degree of uncertainty due to dependence on multiple external factors , and that the Company is doing its best Sounds a little like someone with an alcohol problem who was asked when they were going to stop drinking. He's already lined up his next batch of excuses and they're out of his control.
